NCT03419975View on ClinicalTrials.gov

A Multi-center, Randomized, Blinded Evaluator, Active Control, Parallel, Phase III Study to Evaluate the Efficacy and Safety of TJO-002 in POAG or Ocular Hypertension Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

146

Participants

Timeline

Start Date

April 26, 2016

Primary Completion Date

December 28, 2017

Study Completion Date

June 1, 2018

Conditions
Primary Open-angle GlaucomaOcular Hypertension
Interventions
DRUG

TJO-002

Administrate the drugs for clinical trial one drop once daily at the same time (9 p.m. ± 1 hour) for a study eye

DRUG

Latanoprost

Administrate the drugs for clinical trial one drop once daily at the same time (9 p.m. ± 1 hour) for a study eye

Trial Locations (1)

Unknown

Chan Yun, Kim, Seoul

All Listed Sponsors
lead

Taejoon Pharmaceutical Co., Ltd.

INDUSTRY

NCT03419975 - A Multi-center, Randomized, Blinded Evaluator, Active Control, Parallel, Phase III Study to Evaluate the Efficacy and Safety of TJO-002 in POAG or Ocular Hypertension Patients | Biotech Hunter | Biotech Hunter